Mirum tees up Livmarli label expansion on Phase III liver disease study success

Phase 3positiveLivmarliPositive

AI Analysis

Summary

Mirum announced positive Phase III study results for Livmarli in liver disease, positioning the company for label expansion. The successful trial data supports expanded clinical use of the drug.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.80

Phase IIIliver diseaselabel expansionclinical trial success

Related Companies

$MIRM

Read the original article

Published by yahoo_finance on October 12, 2026 3:48 PM

Read Original